方法：采用回顾性临床病例对照研究，60例68眼随机分为3组，其中曲伏前列素组20例22眼，拉坦前列素组20例25眼，贝美前列素组20例21眼。测量用药前及用药6mo后的中央角膜厚度。

结果：三组用药后平均中央角膜厚度与用药前比较均明显变薄， 曲伏前列素组从525±36.45μm下降至510±27.87μm(t=8.11，P<0.05)，拉坦前列素组从530±26.65μm下降至512±22.27μm(t=5.62，P<0.05)，贝美前列素组从534±47.35μm下降至516±19.56μm(t=5.62，P<0.05)。用药后6mo，三组间平均中央角膜厚度比较无明显差别(F=0.205，P=0.544)。

结论：局部应用前列腺素类药物可以使中央角膜厚度变薄。

METHODS: By clinical retrospective case control study, patients with primary open angle glaucoma(POAG)were randomly classified for 3 groups: Twenty patients(22 eyes)were treated with Travoprost, 20 patients(25 eyes)were treated with Latanoprost, and 20 patients(21 eyes)were treated with bimatoprost. CCT before and 6 months after the treatments was observed.

RESULTS: The CCT of 3 groups had decreased markedly after 6 months. Travoprost group decreased from 525±36.45μm to 510±27.87μm(t=8.11, P=0.001), Latanoprost decreased from 30±26.65μm to 512±22.27μm(t=7.34, P=0.001), and Bimatoprost reduced from 534±47.35μm to 516±19.56μm(t=5.62, P=0.001). The effectiveness of the treatments did not differ significantly when the three groups were compared(F=0.205, P=0.544).

CONCLUSION: The study demonstrated that use of prostaglandins could reduce the CCT.